IMiDS can increase the number of activated NK cells through the upregulation of co-stimulatory surface molecules such as CD80, CD83 and CD86 and the restoration of NKG2D activating ligand receptor on CLL NK cells as well as the upregulation of natural cytotoxicity receptor NKp30 in both CLL and FL patients [74,75]. Here, CD86 is linked to B-cell chronic lymphocytic leukemia.